3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
21
Triple Negative Breast Neoplasms
6
Ovarian Neoplasms
6
Pancreatic Neoplasms
4
Neoplasm Metastasis
3
Neoplasms
2
Fallopian Tube Neoplasms
2
Urologic Neoplasms
1
Unilateral Breast Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Neoplasm, Residual
1
Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
HER2-negative Metastatic Breast Cancer
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Interventions
Trastuzumab
5
Carboplatin
5
Docetaxel
4
pertuzumab
3
Paclitaxel
3
Cyclophosphamide
3
pembrolizumab
2
Epirubicin
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
taxane
1
talazoparib
1
sarilumab
1
pyrotinib
1
pirarubicin
1
pexidartinib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
niraparib
×
Breast
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled